<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786770</url>
  </required_header>
  <id_info>
    <org_study_id>1820202</org_study_id>
    <nct_id>NCT03786770</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)</brief_title>
  <official_title>A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of
      moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of
      the glabellar complex.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Actual">March 9, 2020</completion_date>
  <primary_completion_date type="Actual">March 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of DAXI for injection in the treatment of dynamic FHL</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>Proportion of subjects achieving a score of 0 or 1 (none or mild) in severity on the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS) scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of DAXI for injection in the treatment of dynamic FHL</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>Incidence, severity, and relationship to study drug of treatment-emergent AEs (TEAEs) and serious adverse events (SAEs) during the overall study duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the responder rate of DAXI for injection in the treatment of FHL in conjunction with treatment for GL</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>Proportion of subjects achieving an improvement of at least 1 point from baseline on the IGA FHWS.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Frown Lines</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DaxibotulinumtoxinA for injection</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Cohort 1: Dose A</arm_group_label>
    <arm_group_label>Cohort 2: Dose B</arm_group_label>
    <arm_group_label>Cohort 3: Dose C</arm_group_label>
    <arm_group_label>Cohort 4: Dose D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent consistent with ICH-GCP guidelines and local laws,
             including authorization to release health information, signed prior to any study
             procedures being performed

          -  Be outpatient, male or female subjects, in good general health, 18-65 years of age

          -  Have a score of moderate (2) or severe (3) FHL during maximum contraction (eyebrow
             elevation) as assessed by the IGA-FHWS

          -  Have a score of moderate (2) or severe (3) FHL during maximum contraction (eyebrow
             elevation) as assessed by the PFHWS

          -  Have a score of moderate (2) or severe (3) GL during maximum frown based on the
             IGA-FWS scale

          -  Have a score of moderate (2) or severe (3) on GL during maximum frown as assessed by
             the PFWS

          -  Be willing to refrain from receiving facial fillers, laser treatments, use of any
             product that affects skin remodeling, or a product that may cause an active dermal
             response in the treatment areas (e.g., above the inferior orbital rim) from screening
             through the end of the study

          -  Able to understand the requirements of the study and be willing and able to follow all
             study procedures, attend all scheduled visits, and successfully complete the study.

        Exclusion Criteria:

          -  Active skin disease, infections, or inflammation at the injection sites

          -  Plans to receive botulinum toxin type A anywhere in the face (other than study
             treatment) from screening through the end of the study

          -  History of clinically significant bleeding disorders

          -  Non-ablative laser or light treatments, microdermabrasion, or chemical peels (medium
             depth or deeper, for example TCA or phenol) in the treatment areas within 3 months
             before enrollment through the end of the study

          -  Clinically significant laboratory values at screening that may interfere with a
             subject's ability to complete the study as determined by the investigator

          -  History of upper or lower lid blepharoplasty or brow lift

          -  Prior periorbital or forehead surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boca Raton site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coral Gables site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto, Ontario site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodbridge, Ontario site</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Forehead Lines</keyword>
  <keyword>Glabellar Lines</keyword>
  <keyword>Frown Lines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

